AMGEN INC 8-K

What Happened Amgen Inc. announced on January 30, 2026 that it entered into a Termination Agreement with Kyowa Kirin Co., Ltd. to terminate the License and Collaboration Agreement originally dated June 1, 2021. The termination will become effective only upon receipt of the required regulatory approval. The Termination Agreement is filed as Exhibit 10.1 to the 8-K (portions redacted for confidentiality).

Key Details

• Termination Agreement dated January 30, 2026 between Amgen and Kyowa Kirin.
• Original License and Collaboration Agreement dated June 1, 2021.
• Termination becomes effective upon receipt of regulatory approval (no effective date until approval).
• Termination Agreement is included as Exhibit 10.1 to the 8-K; portions of the exhibit are omitted as confidential/non-material.

Why It Matters This filing notifies investors that Amgen and Kyowa Kirin have agreed to unwind a previously disclosed collaboration, but the termination is conditional on regulatory approval and the 8-K does not disclose financial terms or operational impacts. Investors should watch for subsequent regulatory notices and additional Amgen filings that disclose any changes to development rights, milestone or royalty arrangements, or financial effects arising from the termination.